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Abstract The role of the chemical-physical characteristics of the prosthetic biomaterials 
in the biomechanics of a total joint replacement is presented. The following 
main biomaterials are discussed: (1) the ultra high molecular weight 
polyethylene (UHMWPE): standard, cross linked, stabilized with vitamin 
E; (2) the polymethylmethacrylate (PMMA): standard cement, cements 
with low temperature polymerization, antibiotic-loaded cements; (3) the 
ceramic materials: oxide ceramics (over all Alumina-Zirconia Composites) 
as components of the artificial joint, and calcium phosphate ceramics as 
osteoconductive coatings on metal alloy components; (4) the metallic materials: 
stainless steel, alloys based on the Co-Cr system, Ti and its alloys. To know 
how the biomaterial modifies its mechanical properties in accordance with 
the manufacturing, sterilization, storage, handling, contact with- and reaction 
to the patient’s tissues and fluids is fundamental for the researchers and the 
surgeons, allowing a successful implant.
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Biomaterials for Total Joint 
Replacements
Elena M. Brach del Prever, Luigi Costa, 
Corrado Piconi, Marcello Baricco, 
and Alessandro Massè
The European Society for Biomaterials defines 
a biomaterial “a material that interacts with the 
biological systems to evaluate, treat, reinforce 
or replace a tissue, organ or function of the 
organism” and the biocompatibility “the abil-
ity of a material to perform with an appropri-
ate host response in a specific application” [1]. 
Recently, a new concept of biocompatibility was 
suggested in relation with the new technolo-
gies [2] and the fourth generation of biomateri-
als, the so-called smart or biomimetic materials 
[3]. Biocompatibility of a biomaterials is tested 
by in vitro screening, in vivo testing and clini-
cal monitoring; each step evaluates the biologi-
cal response in different conditions. In vivo, few 
seconds after the implantation, the biomaterial is 
rapidly adsorbed by proteins, whose quantity and 
organisation depend on the characteristics of the 
biomaterial, such as chemical composition of the 
bulk and surface, surface geometry, chemical and 
physical properties and the properties of the pro-
teins. The host cells contact the protein layer: in 
total joint replacements, bone cells ongrowing on 
the prosthetic surface determine an osseointegra-
tion, fibrous cells as fibrous fixation. The produc-
tion of wear and degradation particles, inevitable 
in all TJR, determines a biological response 
defined as bioreactivity; its major determinants 
are the particle size, concentration, surface chem-
ical composition, surface energy, surface charge, 
surface roughness, particle shape and nature of 
adsorbed proteins; genetics might be influent in 
determining the biological response. The wear 
particles activate macrophages and initiate the 
inflammatory cascade resulting in bone loss and 
reduced bone production, prosthetic loosening 
and eventual TJR failure. New therapeutic strate-
gies try to diminish particle- associated peripros-
thetic inflammation modifying the monocyte/
macrophages migration and activation [4].
Some wear metal particles are able to accu-
mulate in the periprosthetic tissues and enter in 
the bloodstream, and can be responsible for chro-
mosomal aberrations and DNA damage, which 
may promote cancerogenesis. Genotoxicity or 
mutagenicity, and/or carcinogenicity were dem-
onstrated in experimental studies with CoCr 
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alloys, in accordance with epidemiological stud-
ies concerning the association of exposure to 
chromate particles and the incidence of nasal and 
lung cancer. Nickel is demonstrated to be geno-
toxic in vitro and carcinogenetic in vivo (lung and 
ethmoidal bone). However, after an average of 13 
years and up to 25 years of follow-up, no increased 
cancer risk in patients with conventional total hip 
replacements was demonstrated [5–7].
In some previously sensitised patients, abra-
sion and corrosion products could behave like 
haptens, and the complex may stimulate memory-
lymphocytes initiating an inflammatory process. In 
particular, metal particles can either act as haptens 
bindings to protein carriers, or as adjutants, forming 
insoluble complexes with the antigens, initiating an 
immune response. Hypersensitivity reactions have 
been reported to be more frequent with stainless-
steel or cobalt alloy than with titanium alloy; hyper-
sensitivity to polymethylmethacrylate was found to 
be 50 % in failed total hip implants.
The probability of developing a metal allergy 
seems to be higher post-operatively and the risk 
further increased when failed implants were 
compared with stable TJRs [8]
 Ultra High Molecular Weight 
Polyethylene (UHMWPE)
A macromolecular chain of polyethylene (PE) 
can be represented by the following formula:
~(CH2-CH2)n~
There are many types of PE, all characterised 
by the same structural unit, but with different 
lengths, different space arrangements and different 
chain imperfections. In total joint replacements, 
the Ultra High Molecular Weight Polyethylene 
(UHMWPE) is used because of its biocompatibility 
and excellent mechanical properties. UHMWPE is 
a high density PE (HDPE) with molecular mass 
more than 2.000.000 amu; it is a semi-crystalline 
polymer with a set of ordered regions (crystal-
line lamellae), where macromolecules are tightly 
packed and the density is at its highest, embedded 
in a disordered amorphous phase, where macro-
molecules are randomly arranged and orientated. 
Table 5.1 shows the required characteristics of 
orthopaedic UHMWPE according to ASTM F648-
10. With an exception for the density (crystallinity 
degree is expressed as the percentage by weight of 
the crystalline regions present in the whole poly-
mer), there are virtually no superior limits for the 
other characteristics. This means that UHMWPE 
can have different starting characteristics, whether 
chemical, physical or mechanical. It is worth men-
tioning that the determination of these characteris-
tics is carried out on the original material, before 
processing and sterilisation [9–11].
 Processing
The UHMWPE powder coming from the 
Ziegler- Natta polymerisation plant is processed 
by compression moulding and ram extrusion: 
both techniques use high pressure and controlled 
heating and cooling cycles, and do not signifi-
cantly modify chemical, physical and structural 
characteristics of the starting polymer, with the 
exception of crystallinity (which is normally 
much higher in the pristine powder). Therefore 
all prosthetic components, ready to be sterilised, 
still retain all properties of the starting material.
Table 5.1 Requirements for UHMWPE fabricated forms, according to ASTM F 648-10a
Property (unit) Test method
Requirement for 
type I (GUR 1020)
Requirement for 
type II (GUR 1050)
Density (g/cm3) ASTM D-792 0.927–0.944 0.927–0.944
Ash (mg/kg) (maximum) 125 125
  Tensile strength (MPa) ASTM D 638
  Ultimate (minimum) 40 40
Yield (minimum) 21 19
Elongation (%) ASTM D 638 380 340
Izod impact strength (kJ/m2) (min) ASTM F 648–10 Annex A1 126 73
Charpy impact strength (kJ/m2) (min) ISO/CD 11542/2.3 180 90
E.M. Brach del Prever et al.
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 Sterilisation
The main sterilisation processes used nowadays 
employ ethylene oxide (EtO), gas-plasma (GP) 
and high-energy radiation (gamma radiation and 
electron beam) [9–11].
EtO and GP are surface sterilization meth-
ods and do not significantly affect the physical, 
chemical and mechanical properties of prosthetic 
components. GP is based on the action of ionized 
gas (i.e. hydrogen peroxide or peracetic acid).
Gamma radiations are emitted during decay of 
a 60Co unstable nucleus. The dose absorbed by 
prosthetic components is about 25–30 kGy and 
depends upon the geometry of the sample and its 
position in relation with the source.
Electron beam is produced by thermally excit-
ing a tungsten filament; the emitted electrons are 
accelerated by electric fields up to 10 MeV and 
then conveyed onto the material to be sterilised. 
The advantages of this method are the easy con-
trol of the apparatus and the very short period of 
treatment (seconds).
 Degradation and Oxidation
Gamma radiation and electron beam have a mean 
energy some orders of magnitude higher than that 
of polymeric chemical bonds and therefore gen-
erate the scission of some chemical bonds of the 
UHMWPE and formation of free radicals. If even 
a single C-C bond of the UHMWPE chain is bro-
ken and 2° CH2 ~ radicals are formed, the length 
of the chain and consequently the molecular mass 
decrease, with worsening of some chemical and 
physical material characteristics. This process is 
called degradation and in presence of oxygen, 
oxidation, which involves free radicals (Fig. 5.1).
The oxidative process depends on the radicals 
(formed during sterilisation) and on the amount 
of oxygen diffused into the PE components from 
the atmosphere during processing, sterilisation if 
conducted in presence of air and storage [12].
The distribution of oxidative products in the 
prosthetic component depends from the follow-
ing variables: rate at which radiations is supplied, 
temperature of the sterilisation chamber, amount 
of oxygen present in the polymer when irradi-
ated and diffused afterwards. Both in new and 
retrieved component, a crown effect or white band 
was the macroscopic evidence of this oxidation, 
responsible for many severe failures (delamina-
tion and fracture) during service in vivo in years 
‘90’. Unfortunately, the first dramatic failures of 
UHMWPE components in the mid 1980s were 
attributed to inadequate mechanical properties of 
the UHMWPE, despite the evidence that these 
properties were much better than those required 
by ASTM F648.
 Packaging
An adequate packaging of the components is 
mandatory to assure the correct atmosphere in 
accordance with the chosen sterilization process; 
the packaging could be critical when high energy 
H2C-CH2-CH2 H2C—CH—CH2
H2C—CH=CH2
stable products
+ Vit E
+ Hγ o e-beam ketones, alchols,
carboxylic acids, esters
+
H2C—CH—CH2
—
—
—
CH2
CH2
CH
Fig. 5.1 The degradation of 
the UHMWPE induced by 
high energy radiation 
sterilization; in presence of 
oxygen, from the 
atmosphere, the process is 
called oxidation. Vitamin E 
is able to stabilize against 
oxidation
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radiation in vacuum or inert gases to reduce oxi-
dation is used. Currently employed packaging 
can be included in three categories [13]:
 – Gas-permeable packaging, adequate for EtO 
and GP sterilization: a polyethylene tere-
phthalate (PET) blister with a Tyvek® cover;
 – Polymer barrier packaging: multi-layer plastic 
bags with gas-barrier properties with limited 
but measurable permeability to oxygen;
 – Aluminium barrier packaging: virtually 
impermeable to gases.
Ultimately, a complete absence of oxidation is 
obtained only by gas-sterilisation.
 Debris and Diffusion
Polyethylene debris are particles loss due to fric-
tion, caused by the reciprocal movement of the 
loaded articular surfaces: for equal mechanical 
stress, material and interface, abrasion is func-
tion of time. Whereas dramatic failures due to 
anomalous wear of heavily oxidised polyethyl-
ene have become quite uncommon nowadays, 
the production of abraded particles remains a 
problem in young patients whose life expectancy 
and quality of life are very high. The debris initi-
ate an inflammatory reaction, the formation of a 
loosening membrane and a secondary osteolysis. 
The junctional tissue depends from number, size 
and chemical structures of UHMWPE debris. 
While pointing out that this topic is in continu-
ous development, it is important to realise that 
the debris is not just simple UHMWPE particles, 
but biologically active particles whose surface 
interact with the human tissues according with 
their macro and micromorphology, contact area, 
molecules adsorpted on their surface, superficial 
hydrophilic and hydrophobic character, release 
of free radicals and time [9–11].
A process of adsorption and deep diffusion 
into the UHMWPE prosthetic components of 
organic molecules present in the synovial liquid, 
such as cholesterol, ester of cholesterol, squalene, 
β-carotene, takes place in vivo. This diffusion 
explains the yellowish colour in some retrieved 
components [14].
 Crosslinked UHMWPE
To increase the abrasion resistance, crosslinked 
UHMWPE (X-PE) appeared on the market in the 
late 1990s [9–11, 15]. Crosslinking of a polymer 
is the linking of two or more molecular chains 
by means of chemical covalent bonds: macro 
radical species, formed by treatment with high 
energy, react with vinyl double bonds, linking the 
polymer chains with a C-C stable chemical bond 
and giving Y-crosslink. The X-PE can be repre-
sented as one long, branched molecule with infi-
nite molecular mass and consequent better wear 
resistance properties than standard UHMWPE, 
but also with some lower mechanical properties, 
owing to chemical and physical modifications 
induced by irradiation and heat treatment.
Commercially available X-PEs are obtained 
by different crosslinking processes, mainly based 
on gamma radiation or electron beam at doses 
ranging from 60 to 100 kGy at room temperature 
or in the molten state, depending on the manu-
facturer; the residual radicals are eliminated by 
thermal treatment, sometime at temperature 
below the melting point of the polymer (typically 
at 130 °C) (annealing). The final sterilization is 
obtained by EtO or gas-plasma or, in few cases, 
by gamma radiation in low oxygen environment 
[12].
Due to different crosslinking processes, the 
commercial X-PEs can be very different with 
variable properties, while standard UHMWPE 
has and maintain its properties if processed and 
sterilised in adequate ways.
Even if dramatic oxidation levels are not 
observed in newly produced UHMWPE compo-
nents, it must be kept in mind that also very low 
oxidation levels can lead to significant variations 
in the mechanical properties of the polymer.
 Vitamin E Stabilised UHMWPE
Vitamin E or, better, its synthetic derivative, alfa- 
tocopherol, is employed to stabilize UHMWPE 
against oxidation (ASTM F2695-12). As already 
pointed out, PE is easily subject to oxidation, 
which strongly compromises their mechani-
cal properties. The oxidation is basically due to 
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the reaction between macroradicals and oxygen 
diffused into the polymer from the surround-
ing atmosphere; Vitamin E decreases the macro 
alkyl radicals available to react with the oxygen 
and thus to a significant slowdown of the oxi-
dative cascade [9–11, 15–17]. Unfortunately, a 
decreased number of available alkyl radicals is 
also responsible for a lower efficiency of cross-
linking at the same radiation dose, but a correct 
vitamin E concentration and radiation dose deter-
mine an oxidatively stable UHMWPE, without 
the need of a further thermal treatment, with 
enough crosslink density and consequent resis-
tance to abrasion.
 Polymethylmethacrylate, 
the Orthopaedic Cement
Orthopaedic cement is basically poly(methyl 
methacrylate) (PMMA) obtained by polymeris-
ing the methyl methacrylate monomer (MMA) 
[18, 19]. Usually it is supplied in two separate 
packages: a brown coloured vial (in order to 
avoid any negative influence of the light on the 
monomer) containing about 20 ml of transparent 
liquid, and one package or two containing 40 g 
of powder. The liquid contains: MMA, usually 
N,N dimethyl-p-toluidine (DMPT) to accelerate 
the polymerisation process in presence of radi-
cals, and traces of hydroquinone to avoid prema-
ture polymerisation of the monomer. The powder 
is formed by pre-synthesised PMMA (at times 
polymethylmethacrylate-styrene as copolymers 
are used), dibenzoyl peroxide (DBP) and barium 
sulphate (or zirconium dioxide), the latter may 
be supplied in a separate package. PMMA is in 
the shape of spherical particles having a vari-
able diameter between 30 and 250 μm; the size 
of the particles determines the viscosity of the 
cement. When the contents of the two packages 
are mixed, DBP initiates the radical process of 
polymerisation through polymerisation accelera-
tor and the effect of polymerisation heat. Barium 
sulphate makes the cement radio-opaque.
Cements produced by different industrial com-
panies have different chemical-physical charac-
teristics and mechanical properties due various 
components and their relative concentrations.
Bone cement preparation is characterised by 
three phases: the wetting phase corresponds to 
mixing the solid part with the liquid, the setting 
phase (divided into ‘dough time’ and ‘work-
ing time’) corresponds to the initial polymeri-
sation process (about 5 % of total), the curing 
phase corresponds to the final hardening phase 
and completion of the polymerisation process. 
During mixing, benzoyl peroxide, present on 
the surface of the PMMA powder, and DMPT 
present in the liquid, interact and the polymeri-
sation process starts, mainly on the surface of 
the pre-synthesised poly(methyl methacrylate). 
Working time starts when a “dough” is obtained 
which no longer sticks to gloves and tempera-
ture increase of the cement is minimal, corre-
sponding to minimal transformation of MMA to 
PMMA. The final polymerisation phase is char-
acterised by the rapid increase of polymerisation 
rate and temperature. The time required for the 
various phases depend mainly on the tempera-
ture in the operating theatre: a 10 °C increase 
causes polymerisation to start twice as quickly, 
cutting mixing times by half. After polymeriza-
tion, less than 5 % of MMA remains free and this 
percentage may slowly spread into the body. The 
MMA polymerization reaction is exothermic; the 
high temperature favours DBP decomposition 
leading to an increase in radical formation and 
consequently an increase in polymerization pro-
cess. Therefore, polymerization speed is initially 
minimal and gradually increases. Where process-
ing carried out in adiabatic conditions, the bone 
cement temperature would reach 160 °C. The 
actual temperature reached by the cement dur-
ing the surgery depends on the balance between 
quantity and speed with which the heat is pro-
duced, and how easily the heat is dispersed from 
the surface into surrounding tissues. At the inter-
face with spongy bone, due to vascularisation 
and the trabecular shape of the bone itself, tem-
peratures of 60 °C can be reached, while in the 
centre of the mass of cement the temperature is 
higher than 100 °C. Schematically cement pro-
duces heat in function of the used amount, and 
the temperature at the interface increases with the 
higher quantity of cement. Based on this assump-
tion, an adequate surgical technique can lower 
the temperature at the interface by using both 
5 Biomaterials for Total Joint Replacements
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an adequate and not too thick layer of cement, 
and washing liquids in the final polymerization 
phase. Some cements are declared as “low tem-
perature polymerization”. They are characterised 
by a lower ratio monomer MMA/polymer that 
proportionally lowers the heat developed during 
transformation of monomer into polymer. High 
temperature is sought when the cement is used 
as adjuvant in bone tumours to ensure “sterilisa-
tion” of a bone surface from which the tumour 
has been removed; therefore in oncological sur-
gery, standard PMMA is useful.
During polymerization reaction, a theoretical 
volumetric shrinking of the PMMA takes place 
proportional to the amount of MMA used; in the 
orthopaedic cement, the volumetric shrinking is 
7 % of the initial volume. Another characteristic 
of cement is the porosity due to CO2 formed dur-
ing decomposition of the initiator, MMA mono-
mer evaporation, air-bubble formed during hand 
preparation of the mixture, and the expansion 
due to temperature increase during polymerisa-
tion. In actual orthopaedic cements, the vacuum 
technique preparation decreases air- bubble for-
mation; other factors cannot be eliminated.
Antibiotic-loaded cements are used in order to 
obtain a greater quantity of local antibiotic and 
to reduce the systemic quantity, thereby decreas-
ing general toxicity; they are whether industrially 
packaged or prepared in the operating theatre 
according to the antibiogramme [20]. The state 
of the art on how the antibiotic manages to act 
is the following: the antibiotic, when soluble in 
water, dissolves from the surface of PMMA into 
the tissues; antibiotic molecules of notable size 
are physically blocked inside the bone cement 
and, therefore, cannot spread from inside the 
cement to the surface. The dissolution process 
depends on the type of antibiotic, on the charac-
teristic of the surface of the cement and on the 
way the cement itself is prepared. When the anti-
biotic is added to the cement during preparation 
of the cement itself, that is in the operating room, 
only a small part of the antibiotic molecules are 
casually on the surface of the cement and will be 
able to dissolute. This process explains why the 
actual antibiotic-loaded cements have a limited 
antiseptical action.
 Ceramic Biomaterials
Ceramics are solid materials, which have as 
their essential component inorganic non-metallic 
materials. In joint replacements oxide ceramics 
are used as components of the artificial joint (ball 
heads and inserts in hip replacements, femo-
ral component in knee replacements, glenoid in 
shoulder replacements), while calcium phosphate 
ceramics (CPCs) are used as osteoconductive 
coatings on metal alloy components.
 Oxide Ceramics
Two ceramic oxides are used in joint replace-
ments: alumina and zirconia. Both are ionic sol-
ids, the high energy of the chemical bond giving 
them a high resistance to the corrosion, hardness, 
stiffness. The chemical stability of these oxides 
is the root of the excellent biological safety of 
their wear debris, a behaviour relevant for their 
intended use in arthroprostheses’ bearings [21]. 
So far (end 2014) more that 80 % of Total Hip 
Replacements (THR) in Italy, France, Germany 
and Austria are making use of ceramic ball 
heads, as well as in Japan and Korea, while in 
the USA ceramic ball heads are used in about 
20 % of THR only. The market leader CeramTec 
GmbH (Plochingen, Germany) declared to have 
sold by 2014 ten million of BIOLOX® ceramic 
bearing components. The behaviour of selected 
oxide ceramics is shown in Table 5.2.
 Alumina
The development of alumina (aluminium oxide – 
Al2O3) as a biomaterial began in the mid-60s, the 
behaviour of alumina components (say total hip 
replacement – THR ball heads) were improved 
continuously over more than 40 years of clini-
cal use, making alumina one of the better char-
acterised biomaterials [22]. The material used in 
biomedical application is α-alumina, known as 
corundum, one of the most stable oxides, unaf-
fected by corrosion (e.g. absence of ion release 
from bulk materials and from wear debris) in 
the most adverse conditions. The biocompat-
ibility of alumina is a well-established property. 
E.M. Brach del Prever et al.
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
Notwithstanding the improvements introduced 
in the processing of alumina ceramics for clini-
cal applications, the weak point of this alumina 
remains its low toughness that limits the flex-
ibility in design of alumina components. For this 
reason, alumina components today are used in 
about 15–20 % only of the ceramic implants, the 
balance being alumina-zirconia composites (see 
section on “Alumina-Zirconia Composites”).
 Zirconia
Zirconia (zirconium dioxide – ZrO2) ceramics 
were developed and introduced in clinical use 
in the late 80s to overcome the toughness limi-
tation of alumina. The early developments were 
oriented towards Magnesia-Partially Stabilised 
Zirconia (Mg-PSZ), in which the tetrago-
nal phase is present within large cubic grains 
(Ø40 ÷ 50 μm) forming the matrix, a coarse struc-
ture that may negatively influence the wear prop-
erties of joints. Most of the developments were 
focused on Yttria stabilised Tetragonal Zirconia 
Polycrystal (YTZP), a ceramic constituted by 
tetragonal grains some hundreds of nanometer in 
size which has been a standard bearing material 
in orthopaedics up to the year 2000. The struc-
tural applications of zirconia ceramics are based 
on the constrained tetragonal- to- monoclinic 
(t-m) phase transformation, which acts as a dissi-
pative mechanism for fracture energy. Briefly, the 
phase transformation is associated to the expan-
sion of zirconia lattice (4 vol% in free grains) 
and to its change in shape of the crystal cells that 
have to overcome the constraint of the matrix 
grains. The process takes place at the expenses of 
the elastic energy field (tensile) associated to the 
developing crack, that to advance has in addition 
to win the compressive stress field due to grain 
t-m transformation. At a macroscopic level, this 
results in a toughened ceramic material, having 
bending strength twice the one of alumina (900–
1100 MPa Vs. 500–600 MPa).
The t-m phase transformation that gives to 
zirconia its interesting behaviour is also its main 
drawback: zirconia is a metastable material, and 
its clinical outcomes were contradictory [23]. 
The worldwide recall of the zirconia Prozyr® 
ball heads made by Saint Gobain Advanced 
Ceramics Desmarquest (Evreux, France) led to 
the practical abandon of zirconia in arthroplasty, 
where thus far it is still used in some niche prod-
ucts only. On the other hand, zirconia has found 
recently a wide field of application as a bioma-
terial in dentistry, for the construction of dental 
implants, and of the structure of crowns, bridges, 
dentures by CAD-CAM processing of presin-
tered blanks [21].
Zirconia is also used as a coating obtained 
by in-situ oxidation of zirconium-2,5Nb alloy 
(Oxinium®, Smith & Nephew, London, UK). 
In spite of many claims of good wear proper-
ties following total knee replacement either total 
hip replacement with OxZr femoral component, 
doubts have been recently raised about this tech-
nology in terms of wear reduction both in terms 
cost/benefits gains. Namely, due to its thickness 
Table 5.2 Indicative values of selected properties of selected oxide bioceramics
Properties (unit) Unit BIOLOX®forte Prozyr® BIOLOX®delta
Usual name Alumina Zirconia
Y-TZP
Alumina Matrix 
Composite (AMC)
Chemical composition wt % >99.8 Alpha-Alumina ZrO2 + 5,1 % 
Y2O3
Al2O3: 74
Y-TZP: 24
Other oxides: 2
Density g/cm3 3.97 6.08 4.37
Average grain size μm 1.75 <0.5 0.56 (Al2O3)
0.15 (Y-TZP)
Bending strength MPa 630 >1500 1390
Fracture toughness MPa m½ 3.2 9 6.5
Elastic modulus GPa 407 200 358
Hardness HV 1975 1200 1760
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(5 μm) the surface zirconia scale can be easily 
scratched by third bodies, leading to the increased 
wear of the polyethylene counterface [24].
 Alumina-Zirconia Composites
The abandon of zirconia opened a technological 
gap in arthroplasty. Then, manufacturers focused 
their attention of alumina zirconia composites, 
especially on two classes of materials called 
Zirconia-Toughened Alumina (ZTA) when alu-
mina is the main component and zirconia the bal-
ance, either Alumina-Toughened Zirconia (ATZ) 
when the main component is zirconia.
The first material of this class used in clinics is 
BIOLOX®delta (Ceramtec GmbH, Plochingen, 
Germany), which is formed by a matrix of chro-
mia-doped alumina containing 17 vol% Y-TZP 
and 1 vol% of strontium zirconate platelets. For 
its peculiar microstructure, this material do not 
belong to any of the formerly described classes, 
and was identified as AMC: Alumina Matrix 
Composite. The finely and homogenous distribu-
tion of Y-TZP both of the platelets is obtained by 
nucleation within the alumina matrix during the 
sintering cycle.
The high bending strength and toughness of 
BIOLOX®delta in comparison with alumina 
and Y-TZP is due to the constrained t-m trans-
formation of the zirconia grains: the transforma-
tion imply the compressive deformation of the 
alumina matrix that has an elastic modulus (e.g. 
stiffness) twice the Y-TZP one (407 GPa Vs. 
200 GPa). This increase the energy dissipated in 
the phase transformation. In addition, the plate-
lets in BIOLOX®delta having width/length ratio 
1:10 perform as a fibres reinforcing the material 
contributing to increase the material toughness. 
By December 2014 more than four million ball 
heads, inserts and condyles for knee replace-
ments made out BIOLOX®delta have been sold 
worldwide, making this composite the standard 
“ceramic” in arthroplasty.
 Nitride Ceramics
While titanium nitride (TiN) is clinical since a 
long while as a protective coating on metallic 
component of joint replacement bearings, bulk 
silicon nitride (Si3N4) has been tested for use in 
THR cups coupled to metallic either ceramic ball 
heads, but the future of this ceramic in arthro-
plasty remains still unclear [25].
 Complications with Ceramic Bearings
Due to the improvements introduced in manufac-
turing, fractures of ceramic composites is today 
a very rare event. Arthroprostheses Registry data 
show that revision for fracture of ceramic compo-
nent occurs with a frequency lower that the one 
of stem/neck fractures, either of collapse of the 
polyethylene inlays [26]. Fractures are typically 
associated to severe trauma either to technical 
errors in handling the ceramic components. Insert 
fractures are especially due to intraoperative mis-
positioning while the orientation of the cup is 
the reason of edge loading of the bearing com-
ponents. Recently much attention was devoted 
to noises from THR bearings. Spectrum analysis 
demonstrated that the acoustical vibrations are 
depending on specific features of the implants. 
This explains also the prevalence of the prob-
lem in some Countries and its absence in others, 
likely due to the distribution of the devices [27].
 Calcium Phosphate Ceramics
Calcium phosphate ceramics (CPCs) are since a 
long time used to give bone-bonding behaviour 
to the surfaces of metallic joint replacements 
(e.g. on THR stems) to enhance bony fixation. 
CPC osteoconductive coatings are a well estab-
lished technology in joint replacements and long 
term follow-ups confirm the results obtained 
in early works [28]. CPC are a family of com-
pound with different in vivo behaviour depend-
ing on a number of parameters especially on 
Ca/P ratio the most stable being Hydroxyapatite 
Ca10(PO4)6(OH)2 [29].
Osteoconductive CP coatings are made by 
plasma spray. A critical aspect in this technol-
ogy is the Ca/P ratio of the starting powder and 
its crystallinity. Powder experience a severe 
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 heating/cooling thermal cycle during this pro-
cess. Formation of amorphous phases and of 
resorbable calcium phosphate ceramic (CPC) 
compounds, segregation of CaO and oxidation 
reactions must be carefully controlled. Namely, 
the rate of bone formation and the resorption 
of coating and its mechanical stability (shear 
strength, bond strength, fatigue life) are depend-
ing on a number of parameters, like e.g. pres-
ence of leachable phases, crystallinity, residual 
 porosity [30].
 Metallic Materials for Joint 
Prosthesis
Metallic materials with industrial relevance for 
joint prostheses belong to three main groups 
[31–36]: (i) stainless steel; (ii) alloys based on 
the Co-Cr system; (iii) Ti and its alloys. (i) The 
austenitic AISI 316 stainless steel was the first 
material used for orthopaedic implants. When it 
is specified as AISI 316 L, the carbon content is 
limited to 0.03 wt% for improving the corrosion 
resistance of this material. (ii) Co-Cr based alloys 
have been used for total joint prostheses since the 
early 1900s and are originating from modifica-
tions of dentistry alloy Vitallium (Haynes Stellite 
alloy N. 21). They combine good mechanical 
properties with a high biocompatibility, due to 
the presence of Cr, which forms spontaneously 
a protective oxide layer. The carbon content in 
the alloy must be carefully controlled, because 
the formation of carbide phases may be detri-
mental for mechanical properties. (iii) Ti and 
Ti-based alloys are widely used as biomaterials 
for their high biocompatibility, mainly due to a 
high corrosion resistance related to the forma-
tion of a passive oxide layer at the surface. Good 
mechanical properties and low density constitute 
an additional benefit for joint prostheses produc-
tion. Commercially pure (cP) Ti is used in differ-
ent grades, as a function of the oxygen content 
as impurity. Common Ti-based alloys contain 
aluminium (Al) and vanadium (V), the last often 
substituted by Niobium (Nb) in order to increase 
biocompatibility. The main components and 
physical properties of most widely used metallic 
biomaterials for joint prosthesis are collected in 
Table 5.3.
The industrial production of metallic com-
ponents for joint prosthesis may be carried out 
in different steps. As a first step, raw metals and 
alloys are processed into stock shapes, such as 
bars, sheet, rods, plates, tubes, wires and pow-
ders. The second processing step is used to tai-
lor the microstructure of the alloy, which is 
strongly related to the mechanical properties of 
the implant, by means of thermo-mechanical 
treatments. The transformation of stock materi-
als into final products may be obtained by invest-
ment casting, machining, forging, and sintering. 
Techniques used to manufacture various alloys to 
produce metallic biomaterials for joint prostheses 
are collected in Table 5.4. Surface coatings aimed 
to improve functional properties of implant (i.e. 
biocompatibility, bone fixation) are often added 
as a final step. Functionality and duration of 
implants in a physiological environment are 
very sensitive to surface properties, which may 
be considered the most important and selective 
aspect for joint prosthesis selection. Surface 
treatments are mainly aimed to increase hard-
ness and strength of the surface layer, in order 
to improve the resistance to wear and corrosion.
Even if metallic biomaterials show good static 
mechanical properties, they may suffer signifi-
cantly for fatigue failures [37]. Fatigue strength 
is defined as the highest periodic stress that does 
not initiate a failure of the material after a given 
number of cycles. For hip prostheses, an average 
of 2 · 106 stress cycles per year can be estimated, 
so that more than 108 cycles may be applied dur-
ing a lifetime. The applied stress for fatigue fail-
ures is in the elastic region of the static loading, 
so that fatigue strength is significantly lower than 
ultimate tensile strength. Metallic biomaterials 
have fatigue strengths in air generally well above 
the minimum required for joint prosthesis appli-
cations. Mechanical properties of most widely 
used metallic biomaterials for joint prostheses 
are collected in Table 5.3, together with those of 
cortical bones for comparison.
Total joint replacements are subjected to 
wear and abrasion so that the resistance against 
them is an important criterion for biomaterials. 
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High carbon Co-Cr based alloys (F75) improve 
significantly mechanical properties after work-
ing, so that small plastic deformations at the 
surface significantly increase the hardness of the 
alloy and, as a consequence, its wear resistance. 
In addition, the presence of fine dispersed hard 
carbides increases the wear resistance of these 
alloys. Oxide films formed by passivation at 
the surface of the Cr and Ti containing alloys 
are generally resistant to abrasion [38]. Load 
required to fracture the oxide surface film is 
lower for Ti-based alloys with respect to Co-Cr 
based alloy.
In conclusion, the ideal alloy should have the 
elastic modulus of bone, the strength of cobalt–
chromium alloys, the corrosion resistance and 
biocompatibility of titanium alloys, and the fab-
rication cost of stainless steels [35, 36]. Each 
material has advantages and disadvantages, 
which drive applications. Stainless steels have 
good corrosion and fatigue resistance in short- 
term applications, have a low cost and they are 
easy to be machined, but tend to be corroded in 
long-term applications, have a high elastic mod-
ulus and can produce Ni and Cr allergy. Co-Cr 
based alloys show long-term corrosion resis-
tance, a high fatigue and wear resistance and a 
good biocompatibility, but they are difficult to 
machine, and thus expensive to process, and, like 
stainless steel, they suffer for a high elastic mod-
ulus and Ni and Cr allergy. Ti-based alloys have 
a low density, joined with a relatively low elastic 
modulus, show the greatest corrosion resistance 
and have an excellent biocompatibility, but they 
have a relatively low shear strength and wear 
resistance and are quite expensive. As far as con-
cern the total hip replacement, Table 5.5 reports 
the types of bearing types implanted in Italy on 
2014 [39].
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